A Phase II Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer
Status:
Recruiting
Trial end date:
2025-02-09
Target enrollment:
Participant gender:
Summary
Data from a prior phase II study of single agent cabozantinib in metastatic, refractory
colorectal cancer (NCT03542877) combined with the compelling preclinical data in colorectal
mouse models utilizing cabozantinib combined with nivolumab have led to this concept for a
clinical trial to combine cabozantinib and nivolumab in patients with metastatic MSS CRC in
the third line setting and beyond.
Phase:
Phase 2
Details
Lead Sponsor:
University of Colorado, Denver
Collaborators:
Bristol-Myers Squibb Criterium, Inc. Exelixis National Cancer Institute (NCI)